New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio
Retrieved on:
Thursday, April 8, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Clinical trials, Other Health, Brain disorders, Rare diseases, Monoclonal antibodies, Medical specialties, Branches of biology, Clinical medicine, Progressive multifocal leukoencephalopathy, Ocrelizumab, PML, Leukoencephalopathy, spinal muscular atrophy, Evrysdi™ (risdiplam), multiple sclerosis, Ocrevus, neuromyelitis optica spectrum disorder, Enspryng™ (satralizumab-mwge), Genentech in neuroscience, Genentech
If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.
Key Points:
- If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.
- Progressive Multifocal Leukoencephalopathy (PML): Although no cases have been seen with Ocrevus treatment in clinical trials, PML may happen with Ocrevus.
- Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms.
- These may include problems with thinking, balance, eyesight, weakness on 1 side of your body, strength, or using your arms or legs.